Skip to content

Xavier Electromyographic Wheelchair Control for Limited Mobility Patients

Xavier Electromyographic Wheelchair Control for Limited Mobility Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04800926
Enrollment
4
Registered
2021-03-16
Start date
2019-01-11
Completion date
2019-10-30
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis

Brief summary

The purpose of this study is to assess the functional mobility and self-reported satisfaction with the Xavier electromyography hands-free wheelchair control system in comparison with a standard joystick.

Interventions

DEVICEXavier wheelchair controller

Controlling a wheelchair using the Xavier surface EMG system

Sponsors

University of Central Florida
CollaboratorOTHER
Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

* ALS diagnosis by revised el Escorial criteria (definite, probable or probable laboratory supported) * Age 18-89 * Limited mobility with use of motorized wheelchair at screening-time * Impairment of hand function limiting the use of a standard joystick control * Caregiver willing to assist with transfers into wheelchair and application of controllers * Ability to attend study visits with a motorized wheelchair * Ability to communicate and answer patient reported outcome measure questions

Exclusion criteria

* Cognitive impairment prohibiting safe independent mobility as defined by an ALS-Cognitive Behavioral Screen (ALS-CBS) score of \<10 or the opinion of the investigator * A sensory impairment prohibiting safe independent mobility in the opinion of the investigator * Allergy to adhesives or electrode gels (required for EMG electrodes) * Skin breakdown over the temporalis muscle that would predispose to further breakdown and/or infection with electrodes * Severe loss of facial muscle functionality or control that would preclude EMG electrode efficacy * Subjects who do not have the capacity to consent

Design outcomes

Primary

MeasureTime frameDescription
Wheelchair Skills Test (WST)approximately 3 daysQuestionnaire

Secondary

MeasureTime frameDescription
Drive testapproximately 3 daysDriving around cones in a controlled environment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026